Andrew Tsai
Recent Articles
What Do Analysts Think About the Biopharma Set on Transforming Psychiatry 04/09/2026
Alto Neuroscience Inc. (ANRO:NYSE) is a clinical-stage biopharmaceutical company focused on transforming psychiatry through novel drug candidates.
How Do Analysts Rate This Biopharma Targeting Psychiatric Disorders 11/20/2025
Alto Neuroscience Inc. (ANRO:NYSE) is developing drug candidates for psychiatric and neurological disorders, utilizing a precision approach rather than a one-size-fits-all method. Read to find out how analysts rate this company.
Co. Speeds Up Development of New Drug for Depression 10/28/2025
Alto Neuroscience Inc. (ANRO:NYSE) plans Phases 2b and 3 trials of its asset, ALTO-207, in treatment-resistant depression, noted a Jefferies report.
Due to permission requirements, not all quotes are shown.
